Ares Bioscience

Acres Biosciences is a private, early-revenue CRO based in San Diego, offering integrated preclinical research services. Its business model is purely service-based, providing cell engineering, assay development, and in vivo studies with a claimed turnaround time as fast as eight weeks. The company positions itself on speed, cost efficiency, and US-based operations, targeting biotech and pharma companies engaged in oncology, fibrosis, metabolic diseases, and infectious disease research. Its value proposition centers on leveraging over 50 years of collective team experience to expedite client drug discovery programs.

Integrated preclinical CRO services platform encompassing Cell Line Engineering (knock-in/out, iPSCs, primary cells), Assay Development (HTS, functional assays), and In Vivo Services (PK/PD, toxicity in oncology, fibrosis, metabolic models).

Operates in the highly competitive preclinical CRO market, competing against global giants (Charles River, Labcorp, etc.), large public CROs (ICON, PPD), and numerous niche specialty providers. Differentiation is based on speed, cost, US location, and collective team experience rather than proprietary technology.